<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892852</url>
  </required_header>
  <id_info>
    <org_study_id>AcuCIPN</org_study_id>
    <nct_id>NCT01892852</nct_id>
  </id_info>
  <brief_title>Acupuncture for Chemotherapy-induced Peripheral Neuropathy</brief_title>
  <official_title>Acupuncture Therapy for Chemotherapy-induced Peripheral Neuropathy in Lymphoma or Multiple Myeloma Patients: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether acupuncture can be effective for
      chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of NCIC-CTC (National Cancer Institute of Canada - Common Toxicity Criteria) 4.0 scale from baseline</measure>
    <time_frame>At baseline, 1, 2, 3, and 7 wks from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of VAS (Visual Analogue Scale) from baseline</measure>
    <time_frame>At baseline, 1, 2, 3, and 7 wks from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of FACT/GOG-Ntx (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity) from baseline</measure>
    <time_frame>At baseline, 1, 2, 3, and 7 wks from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From study enrollment to the last follow-up (up to 7 wks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Peripheral Neuropathy</condition>
  <condition>Toxicity Due to Chemotherapy</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acupuncture treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No other active treatment or sham acupuncture for this symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age and have diagnosis of a lymphoma or multiple myeloma.

          -  Patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2
             according to CTCAE (Common Terminology Criteria for Adverse Events) v 3.0 scale
             (Appendix A) in spite of previous conventional medications, e.g. Neurontin, Cymbalta
             and/or Lyrica. Patients receiving any of conventional medication for this symptoms
             must remain on the same medications throughout the study period.

          -  Patients, or the legal guardians of patients, must have the ability to understand
             Korean, and be ble to provide informed consent.

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, or 2.

          -  If the patient is a woman of child-bearing potential, she must have a negative urine
             pregnancy test and agree to use contraception.

        Exclusion Criteria:

          -  Other diseases that, in the opinion of the investigators, can cause peripheral
             neuropathy, such as alcoholism, diabetes mellitus, and HIV.

          -  Current active treatment for lymphoma or multiple myeloma

          -  Ongoing local infection at or near the acupuncture point adopted in this trial.

          -  Severe immunocompromised patients, leukopenia ( ＜ 4,000/㎣) or neutropenia ( ＜ 1,500/㎣)

          -  Known coagulopathy, thrombocytopenia (＜ 50,000/㎣), and taking heparin (including low
             molecular weight heparin) or Coumadin at any dose.

          -  Serious emotional or mental problems that precludes study entry.

          -  Mental and physical disability that precludes accurate acupuncture.

          -  Serious systemic diseases such as active infection, severe heart disease, uncontrolled
             hypertension and diabetes mellitus.

          -  Cardiac pacemaker.

          -  Pregnant or breastfeeding

          -  Acupuncture therapy within the previous 30 days

          -  Concurrent other complementary and alternative therapy such as herbal agents, high
             dose vitamins, and etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho-Jin Shin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang Woo Han, PhD</last_name>
    <phone>+82-51-240-6835</phone>
    <email>yeast10@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology-Oncology and Center for Integrative Medicine, Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Woo Han, PhD</last_name>
      <phone>+82-51-240-6835</phone>
      <email>yeast10@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Ho-Jin Shin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chang Woo Han, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eui-Hyoung Hwang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acupuncture</keyword>
  <keyword>Traditional Korean Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

